167 related articles for article (PubMed ID: 37760481)
1. Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.
Koinis F; Zafeiriou Z; Messaritakis I; Katsaounis P; Koumarianou A; Kontopodis E; Chantzara E; Aidarinis C; Lazarou A; Christodoulopoulos G; Emmanouilides C; Hatzidaki D; Kallergi G; Georgoulias V; Kotsakis A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760481
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Onstenk W; Sieuwerts AM; Kraan J; Van M; Nieuweboer AJ; Mathijssen RH; Hamberg P; Meulenbeld HJ; De Laere B; Dirix LY; van Soest RJ; Lolkema MP; Martens JW; van Weerden WM; Jenster GW; Foekens JA; de Wit R; Sleijfer S
Eur Urol; 2015 Dec; 68(6):939-45. PubMed ID: 26188394
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.
de Kruijff IE; Sieuwerts AM; Onstenk W; Kraan J; Smid M; Van MN; van der Vlugt-Daane M; Hoop EO; Mathijssen RHJ; Lolkema MP; de Wit R; Hamberg P; Meulenbeld HJ; Beeker A; Creemers GJ; Martens JWM; Sleijfer S
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31434336
[TBL] [Abstract][Full Text] [Related]
4. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Davies CR; Guo T; Burke E; Stankiewicz E; Xu L; Mao X; Scandura G; Rajan P; Tipples K; Alifrangis C; Wimalasingham AG; Galazi M; Crusz S; Powles T; Grey A; Oliver T; Kudahetti S; Shaw G; Berney D; Shamash J; Lu YJ
Front Oncol; 2022; 12():1060864. PubMed ID: 36727071
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
6. Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.
Wang C; Zhang Z; Chong W; Luo R; Myers RE; Gu J; Lin J; Wei Q; Li B; Rebbeck TR; Lu-Yao G; Kelly WK; Yang H
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33450815
[TBL] [Abstract][Full Text] [Related]
7. PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
Gupta S; Halabi S; Yang Q; Roy A; Tubbs A; Gore Y; George DJ; Nanus DM; Antonarakis ES; Danila DC; Szmulewitz RZ; Wenstrup R; Armstrong AJ
Clin Cancer Res; 2023 May; 29(10):1929-1937. PubMed ID: 36897758
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
Messaritakis I; Politaki E; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Kallergi G; Souglakos J; Georgoulias V
PLoS One; 2017; 12(7):e0181211. PubMed ID: 28719656
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
Gurioli G; Conteduca V; Brighi N; Scarpi E; Basso U; Fornarini G; Mosca A; Nicodemo M; Banna GL; Lolli C; Schepisi G; Ravaglia G; Bondi I; Ulivi P; De Giorgi U
BMC Med; 2022 Jan; 20(1):48. PubMed ID: 35101049
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
[TBL] [Abstract][Full Text] [Related]
12. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
[TBL] [Abstract][Full Text] [Related]
14. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
15. Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.
León-Mateos L; Casas H; Abalo A; Vieito M; Abreu M; Anido U; Gómez-Tato A; López R; Abal M; Muinelo-Romay L
Oncotarget; 2017 Aug; 8(33):54708-54721. PubMed ID: 28903376
[TBL] [Abstract][Full Text] [Related]
16. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
Basso U; Facchinetti A; Rossi E; Maruzzo M; Conteduca V; Aieta M; Massari F; Fraccon AP; Mucciarini C; Sava T; Santoni M; Pegoraro C; Durante E; Nicodemo M; Perin A; Bearz A; Gatti C; Fiduccia P; Diminutto A; Barile C; De Giorgi U; Zamarchi R; Zagonel V
Oncologist; 2021 Sep; 26(9):740-750. PubMed ID: 34077597
[TBL] [Abstract][Full Text] [Related]
18. Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer.
Oeyen S; Liégeois V; De Laere B; Buys A; Strijbos M; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Dirix L
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):499-506. PubMed ID: 33230201
[TBL] [Abstract][Full Text] [Related]
19. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.
Messaritakis I; Nikolaou M; Politaki E; Koinis F; Lagoudaki E; Koutsopoulos A; Georgoulia N; Georgoulias V; Kotsakis A
Lung Cancer; 2018 Oct; 124():270-278. PubMed ID: 30268472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
